Comparative Pharmacology
Head-to-head clinical analysis: MYHIBBIN versus SELSUN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYHIBBIN versus SELSUN.
MYHIBBIN vs SELSUN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Myhibbin is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH), thereby blocking the de novo synthesis of guanosine nucleotides. This inhibits T- and B-lymphocyte proliferation and antibody production.
Selenium sulfide is an antifungal agent that inhibits the growth of Malassezia species by reducing selenium to elemental selenium, which is toxic to the fungus. It also reduces sebum production via unknown mechanisms.
MYHIBBIN is not a recognized FDA-approved drug. No standard dosing information is available.
Apply 5-10 mL of 2.5% selenium sulfide lotion to affected areas of scalp, lather with water, leave on for 2-3 minutes, then rinse thoroughly. Use twice weekly for 2 weeks, then once weekly for maintenance.
None Documented
None Documented
Terminal half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours)
Not well defined due to minimal systemic absorption; topical application yields negligible plasma levels.
Renal excretion as unchanged drug (70-80%), biliary/fecal (15-20%)
Selenium sulfide is minimally absorbed; absorbed portions are excreted renally (approx. 80-90%) and fecally (10-20%).
Category C
Category C
Antifungal
Antifungal/Antiseborrheic